[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Virax Biolabs Group Limited (VRAX)

Virax Biolabs Group Limited (VRAX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,205
  • Shares Outstanding, K 4,342
  • Annual Sales, $ 10 K
  • Annual Income, $ -6,060 K
  • EBIT $ 0 M
  • EBITDA $ -6 M
  • 60-Month Beta 1.06
  • Price/Sales 423.78
  • Price/Cash Flow N/A
  • Price/Book 0.26
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 07/01/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.07
  • Number of Estimates 1
  • High Estimate $-0.07
  • Low Estimate $-0.07
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.01%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1202 +130.87%
on 05/06/26
0.5335 -47.99%
on 05/18/26
+0.1425 (+105.56%)
since 04/22/26
3-Month
0.1000 +177.50%
on 04/10/26
0.5335 -47.99%
on 05/18/26
+0.0645 (+30.28%)
since 02/20/26
52-Week
0.1000 +177.50%
on 04/10/26
1.1400 -75.66%
on 07/21/25
-0.7225 (-72.25%)
since 05/22/25

Most Recent Stories

More News
Avalon Advanced Materials and Virax Biolabs Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ORLANDO, FL / ACCESS Newswire / May 15, 2026 / RedChip Companies will air interviews with Avalon Advanced Materials Inc. (OTCQB:AVLNF)(TSX:AVL) and Virax Biolabs Group Limited (Nasdaq:VRAX) on the RedChip...

AVLNF : 0.0466 (+6.64%)
AVL.TO : 0.0650 (+8.33%)
VRAX : 0.2775 (-9.31%)
Virax Biolabs' CEO James Foster Outlines Strategic Priorities and Near-Term Milestones in Letter to Shareholders

Virax Biolabs is advancing a focused strategy centered on ViraxImmuneâ„¢ and a U.S. market-entry pathway, which management believes is not reflected in the Company's current public valuation despite its...

VRAX : 0.2775 (-9.31%)
Virax Biolabs Achieves ISO Certifications, Laying Foundation for Regulated IVD Development and U.S. Clinical Validation

LONDON , March 31, 2026 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company") today announced that Virax Biolabs (UK) Limited, its wholly owned subsidiary, has achieved...

VRAX : 0.2775 (-9.31%)
Virax Biolabs Group Limited Announces Closing of $5 Million Private Placement

LONDON , Dec. 4, 2025 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company dedicated to the advancement of immunology research...

VRAX : 0.2775 (-9.31%)
Virax Biolabs Group Limited Announces $5 Million Private Placement

LONDON , Dec. 3, 2025 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company dedicated to the advancement of immunology research...

VRAX : 0.2775 (-9.31%)
Virax Biolabs' CEO James Foster Outlines Clinical Progress and 2026 Priorities in Latest Annual Letter to Shareholders

Virax Biolabs' proprietary in-development diagnostic technology for post-acute infection syndromes ("PAIS"), such as Long COVID, positions the Company for an important data year ahead, following a series...

VRAX : 0.2775 (-9.31%)
Virax Biolabs Completes UK Clinical Recruitment and Reports Constructive FDA Feedback for ViraxImmuneâ„¢ Study Evaluating T Cell Dysfunction in Post-Acute Infection Syndromes

LONDON , Nov. 3, 2025 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses to and...

VRAX : 0.2775 (-9.31%)
Virax Biolabs Partners with Emory University on ViraxImmuneâ„¢ Clinical Studies; Readies for FDA Pre-Submission Meeting in Early September

LONDON , Aug. 26, 2025 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on immune response detection...

VRAX : 0.2775 (-9.31%)
Virax Biolabs Appoints Iain Miller, PhD as Independent Director to Accelerate Commercial Strategy

LONDON , July 29, 2025 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the detection of immune responses...

VRAX : 0.2775 (-9.31%)
Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency

LONDON , July 18, 2025 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses...

VRAX : 0.2775 (-9.31%)

Business Summary

Virax Biolabs Group Limited is a biotechnology company focused on the prevention, detection, and diagnosis of viral diseases as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus. Virax Biolabs Group Limited is based in London, United Kingdom.

See More

Key Turning Points

3rd Resistance Point 0.3937
2nd Resistance Point 0.3679
1st Resistance Point 0.3227
Last Price 0.2775
1st Support Level 0.2517
2nd Support Level 0.2259
3rd Support Level 0.1807

See More

52-Week High 1.1400
Fibonacci 61.8% 0.7427
Fibonacci 50% 0.6200
Fibonacci 38.2% 0.4973
Last Price 0.2775
52-Week Low 0.1000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.